INTRODUCTION
Occipital neuralgia (ON) is a rare neurological disorder characterized by paroxysmal shooting or stabbing pain in the dermatomes of the greater occipital nerve (GON) or lesser occipital nerve (LON) 5) . Clinical presentation and a temporary improvement with local anesthetic diagnostic block of the GON or LON confirm the diagnosis 5) . The primary treatment of ON is conservative and focuses on reducing secondary muscle tension and improving posture. In cases of continual pain, nerve blocks may be applied or invasive procedures such as occipital nerve stimulation, neurolysis of the occipital nerves, or dorsal root entry zone rhizotomy may be performed 20, 21) . However, the effects of nerve blocks are temporary, and surgical treatments are invasive and have risk and complications 1, 13, 23) . In this study, we present the clinical outcome of 10 patients with ON treated MA, USA) radiofrequency generator. In the operating room, each patient was placed in a sitting position on the procedure table and the posterior neck area was prepped with betadine and aseptically draped with sterile towels. The skin was anesthetized with 5% lidocaine gel. A disposable 22-gauge, 5 cm radiofrequency cannula (Model S-505, NeuroTherm, Inc., Middleton, MA, USA) with a 5 mm active tip was inserted at the levels of both the GON and LON (Fig. 2) . The introducer needle was withdrawn and a disposable RF electrode (Model RFDE-5, NeuroTherm, Inc., Middleton, MA, USA) was advanced. Selective sensory nerve stimulation (50 Hz) showed concordant pain below 0.5 V, which confirmed localization of the PRF electrode.
Motor nerve stimulation was then tested at 2 Hz to exclude the uncorrelated nerve. After stimulation, PRF was performed at 42°C for a total of 240 pulses at each site.
Pain assessment
In all patients, pain was measured before the primary diagnostic block and every month after PRF neuromodulation by the same blinded physician who had made the initial assessments. Pain was assessed using a Visual Analog Scale (VAS) (0 cm-no pain; 10 cm-worst possible pain imagined). Pain was also assessed using the Total Pain Index (TPI) 3) . The TPI is an incorporated pain scale of the weighted intensity and duration of headache attacks.
Statistical analysis
Mean values of the VAS and TPI for pain before the diagnostic block and after PRF neuromodulation were compared using paired t-tests at alevel of 0.05. Two-tailed t-test probabilities reported with p values <0.05 were considered statistically significant.
RESULTS

Patient demographics
The age of the patients ranged between 34 to 70 years with a median age of 52 years. The patient sample consisted of seven (70%) women and three (30%) men. The mean total follow-up time of the patient series was 7.5 months, ranging from 6 to 10 months. The majority of patients presented with bilateral symptoms (60%, 6 of 10 patients) and the remaining four (40%) patients suffered from unilateral ON : two on the right and two on the left side.
Clinical outcomes
Mean VAS scores and mean TPI scores of the 10 treated patients are presented in Table 1 . Significant improvements in pain (VAS, TPI) were found in months 1-6 compared with the prediagnostic block period (p<0.05) (Fig. 3) . The mean VAS score before the pre-diagnostic block period was 6.9 and declined to 1.2 and 0.8 at post PRF and last follow-up period, respectively (p<0.001, and p<0.001). The mean TPI score before the pre-diagnostic block period was 232.7 and declined to 53.7 and 40.6 physical examinations followed by diagnostic tests such as computed tomography and magnetic resonance imaging. None of the patients responded to conservative management, including medications and physical therapy. All patients received GON and LON blocks with 1.0% lidocaine and dexamethasone twice by one week interval. Temporary pain relief of 50% or more was considered a positive response to the nerve blocks, and was one of the most important factors in patient selection for PRF, but the effects were temporary. These patients underwent PRF neuromodulation of the GON and LON for medically intractable ON (Fig. 1) .
Pulsed radiofrequency neuromodulation of the occipital nerves
We performed fluoroscopically guided GON and LON PRF using a NeuroTherm NT1000 (NeuroTherm, Inc., Middleton, . Vision impairment/ ocular pain (67%), tinnitus (33%), dizziness (50%), nausea (50%), and congested nose (17%) can be present because of connections to cranial nerves V, VIII, IX, X, and the cervical sympathetic ganglion 7, 15) . The most common treatment modality for ON is blockade of the GON and LON, which interrupts the pain cycle and reflex muscle spasms and relieves the symptoms. Many studies have shown that occipital nerve block is an effective treatment modality for ON. In a small (n=10) retrospective study by Kuhn et at post PRF and last follow-up period, respectively (p<0.001, and p<0.001) (Fig. 3) .
Of the 10 patients, 8 (80%) completely stopped using analgesics following PRF treatment. One patient (10%) reported a substantial reduction in analgesic requirements and pharmacotherapy was maintained in one patient who had partial recurrence of headaches (Table 1) .
There were neither intraoperative nor postoperative complications that would lead to any type of significant morbidity or mortality. No adverse effects of treatment were observed.
DISCUSSION
ON is a neuralgiform disorder defined as a shooting or stabbing pain originates in the suboccipital region and radiates over the vertex 1) . Hypo-or dysesthesia in the dermatome of the GON Fig. 3 . Graphs showing pain degree changes over a 6 month period according to various pain measurement : visual analogue scale (A), total pain index (B). none of the patients in our study have exhibited any side effects related to our procedure. When performed PRF for ON, electrode approximation of the target nerve is very important. In our study, the puncture sites of the GON and LON were determined by external landmarks as described below 2, 8, 9, 17) . On average, the GON is situated 3.8 cm lateral from the midline and one quarter of the distance along a line connecting the external occipital protuberance to the mastoid (or 2 cm lateral and 2 cm inferior to the external occipital protuberance). The authors used the relationship between the GON and the occipital artery for detecting the GON. At first, the authors identified the occipital artery pulsation about 2.5 cm from the midline, and the GON was located medial to the occipital artery. More detailed information regarding the puncture sites is provided in Fig. 2 . The needle (22G) is introduced until there is bone contact or paresthesia is elicited. Subsequently, the needle is slightly withdrawn. Sensory and motor nerve stimulations are then performed and we can easily find the target nerves.
Study limitations
Several limitations of our study are worth mentioning. First, although the VAS and TPI are validated tools for the quantification of pain, they are subjective outcome measures because they are dependent on personal interpretations and variation. Second, the small sample size limits the power of our outcome observations.
CONCLUSION
The results of this retrospective clinical study support the hypothesis that PRF provides long-term reduction in headaches with minimal procedural risk in selected patients with medically intractable ON. PRF should be considered an effective treatment modality for ON, especially in medically intractable ON patients. Future long-term prospective controlled clinical trials are warranted to establish more definitive conclusions. , the GON was infiltrated with corticosteroids after a positive test block with bupivacaine. The authors observed pain relief of less than 1 week in 10% of patients, 1 week in 30%, 2 weeks in 30%, 1 month in 10%, and more than 2.5 months in 20% of patients. Hammond and Danta 4) observed short-term effects (less than 1 week) in 64% of patients after 1 infiltration with local anesthetic; 36% of the patients reported effects lasting longer than 1 month. All of these effects were of short duration. Injection of depot methylprednisolone into the GON and LON regions produced complete headache relief for periods of only 10-77 days 15) . When nerve block failto relief ON, cervical dorsal root ganglion PRF, and occipital nerve stimulation can be performed for medically intractable ON 4, 7, 14, 15, 22) . Weiner and Reed first reported 13 patients who underwent 17 occipital nerve stimulation procedures for medically intractable ON. With follow-ups ranging from 18 months to 6 years, good to excellent results were seen in 12 of 13 patients as defined by greater than 50% pain relief and requiring little or no pain medications. The 13th patient was explanted following resolution of symptoms 22) . Slavin et al. 12, 13) carried out trial stimulations in 14 patients with medically intractable ON. Definitive neurostimulators were implanted subcutaneously in 10 patients who had reductions in pain of greater than 50%. After a mean follow-up of 22 months, 70% of these patients still had good results. Other studies also report comparable results 6, 11) . However, occipital nerve stimulation may be associated with possible complications such as infection, lead migration, hardware erosions, electrode fractures, disconnections, and sepsis 13) . When a prospective review explored the long-term effects of PRF treatment adjacent to the cervical dorsal root ganglion, the authors found that cervical dorsal root ganglion PRF also have serious complications occurred when a radiofrequency cannula was inserted at the level of the cervical dorsal root ganglion from posterior to frontal under the C-arm fluoroscopic guidance due to insertion into the cervical subarachnoid space or into vessels in this region. Potential risks include infection, stroke, paralysis and cerebrospinal fluid leakage 23) . To date, one case report and one prospective trial have been published concerning PRF neuromodulation in ON 10, 16) . In the case report, the patient showed 70% pain relief lasting 4 months. After recurrence of pain, the PRF neuromodulation procedure was repeated with again 70% pain relief lasting 5 months. Of the 19 patients included in the prospective trial, 68.4%, 57.9%, and 52.6% reported improvement of 50% or more 1, 2, and 6 months after PRF neuromodulation, respectively. There were significant improvements in the use of medication and in quality-of-life parameters.
Compared with the results of other treatment modalities, PRF shows higher efficacy without any complications [18] [19] [20] [21] . PRF treatment is safer, and therefore, should be the preferred treatment for ON 16) . We used PRF for the GON and LON, and we observed pain relief for a minimum of 6 months. Meanwhile,
